Latest News for: ose
Edit
OSE welcomes Dr. Jeff Moore as Senior Partner, Head of Life Sciences (Oxford Science Enterprises PLC)
Public Technologies 29 Sep 2026
Edit
28/09/2026 OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update (OSE Immunotherapeutics SA)
Public Technologies 28 Sep 2026
OSE Immunotherapeutics SA published this content on September 28, 2026, and is ...
Edit
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update (OSE Immunotherapeutics SA)
Public Technologies 28 Sep 2026
OSE Immunotherapeutics SA published this content on September 28, 2026, and is ...
Edit
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
Nasdaq Globe Newswire 28 Sep 2026
Edit
Greece’s ETCS Rail Safety System Still Not Fully Operational 3.5 Years After Tempi
Greek City Times 25 Sep 2026
The mission met relatives of victims, representatives of the Ministry of Infrastructure and Transport, OSE executives, railway employees and independent authorities.
Edit
23/09/2026 OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting (OSE Immunotherapeutics SA)
Public Technologies 23 Sep 2026
OSE Immunotherapeutics SA published this content on September 23, 2026, and is ...
Edit
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting (OSE Immunotherapeutics SA)
Public Technologies 23 Sep 2026
OSE Immunotherapeutics SA published this content on September 23, 2026, and is ...
Edit
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi� in Non-Small Cell ...
Nasdaq Globe Newswire 23 Sep 2026
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi� in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting ... .
Edit
The Daily Record - Dunn
23 Sep 2026
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell ...
Nantes, France, September 23, 2026 – 7.30am CET – OSE Immunotherapeutics SA (ISIN. FR0012127173; Mnemo. OSE), a ....
Edit
Statement by Deputy Chairperson at Launch of OSE-WPS Strategic Plan 2026–2028 (African Union)
Public Technologies 15 Sep 2026
). Your Excellency Ambassador Liberata Mulamula, Special Envoy of The AUC Chairperson on WPS,. Your Excellency Ambassador Amma Twum Amoah, Commissioner for Health, Humanitarian Affairs and social development ... Development Partners; ... Excellencies, ... (noodl.
Edit
09/09/2026 OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients (OSE Immunotherapeutics SA)
Public Technologies 10 Sep 2026
OSE Immunotherapeutics SA published this content on September 09, 2026, and is ...
Edit
Equinor ASA: Ex. dividend first quarter 2026 today – OSE
Nasdaq Globe Newswire 13 Aug 2026
The shares in Equinor ASA (OSE. EQNR; NYSE. EQNR) will as from today be traded on the Oslo Stock Exchange exclusive the first quarter 2026 cash dividend as detailed below ... .
- 1